MedTrace Logo

The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer

NCT05615103 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-11-29

No results posted yet for this study

Summary

Treatment with immune checkpoint inhibitors such as programmed death receptor 1 (PD-1 inhibitors) for advanced and metastatic esophageal squamous cell carcinoma (ESCC) significantly improves patients' overall survival compared to chemotherapy alone. Despite this milestone breakthrough, immunochemotherapy also has known limitations. Indeed, only 45-72% of patients achieved objective responses. It is urgent to find out easily-determined and convenient biomarkers to identify patients who will benefit from such treatment modality. Due to the luminal structure of the esophagus, the exact diameter of esophageal tumor cannot be precisely measured per RECIST 1.1. Moreover, the definition of the metastatic lymph node in which the short-axis lengths should be longer than 1.5 cm hinders the risk of missing the smaller metastatic lymph node foci. Thus, it is difficult to implement morphology-based criteria for evaluating the neoadjuvant immunochemotherapy response. The current study aimed to investigate the role of iPERCIST in predicting tumor response and the short-term overall survival of patients with locally advanced ESCC after neoadjuvant immunochemotherapy.

Conditions

  • Esophageal Cancer

Sponsors & Collaborators

  • First Affiliated Hospital of Shantou University Medical College

    collaborator OTHER

  • Shenzhen People's Hospital

    collaborator OTHER

  • The Affiliated Cancer Hospital of Guangzhou Medical University

    collaborator UNKNOWN

  • Guangdong Provincial People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2023-09-08
Completion
2023-12-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615103 on ClinicalTrials.gov